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S1P1 Receptor Modulation Preserves Vascular Function
in Mesenteric and Coronary Arteries after CPB in the Rat
Independent of Depletion of Lymphocytes
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Martin C. Houwertjes1, Anthony R. Absalom1, Anne H. Epema1, Robert H. Henning2
1Department of Anesthesiology, University of Groningen, University Medical Center Groningen, The Netherlands, 2Department of Clinical Pharmacy and Pharmacology,
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Abstract
Background: Cardiopulmonary bypass (CPB) may induce systemic inflammation and vascular dysfunction. Sphingosine 1-
phosphate (S1P) modulates various vascular and immune responses. Here we explored whether agonists of the S1P
receptors, FTY720 and SEW2871 improve vascular reactivity after CPB in the rat.
Methods: Experiments were done in male Wistar rats (total n = 127). Anesthesia was induced by isoflurane (2.5–3%) and
maintained by fentanyl and midazolam during CPB. After catheterization of the left femoral artery, carotid artery and the
right atrium, normothermic extracorporeal circulation was instituted for 60 minutes. In the first part of the study animals
were euthanized after either 1 hour, 1 day, 2 or 5 days of the recovery period. In second part of the study animals were
euthanized after 1 day of postoperative period. We evaluated the contractile response to phenylephrine (mesenteric
arteries) or to serotonin (coronary artery) and vasodilatory response to acethylcholine (both arteries).
Results: Contractile responses to phenylephrine were reduced at 1 day recovery after CPB and Sham as compared to
healthy control animals (Emax, mN: 7.961.9, 6.561.5, and 11.361.3, respectively). Mainly FTY720, but not SEW2871, caused
lymphopenia in both Sham and CPB groups. In coronary and mesenteric arteries, both FTY720 and SEW2871 normalized
serotonin and phenylephrine-mediated vascular reactivity after CPB (p,0.05) and FTY720 increased relaxation to
acetylcholine as compared with untreated rats that underwent CPB.
Conclusion: Pretreatment with FTY720 or SEW2871 preserves vascular function in mesenteric and coronary artery after CPB.
Therefore, pharmacological activation of S1P1 receptors may provide a promising therapeutic intervention to prevent CPB-
related vascular dysfunction in patients.
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Introduction
Cardiopulmonary bypass (CPB) is a widely used technique
invaluable to thoracic surgery. CPB is however associated with
several side-effects, such as ischemia/reperfusion injury and the
induction of a systemic inflammatory response syndrome, poten-
tially leading to multiple organ dysfunction. Several pathological
mechanisms are involved in the etiology of CPB-related compli-
cations. Contact of blood with the artificial surfaces of extracor-
poreal circulation circuit (ECC) activates an alternative pathway of
complement activation, and induces release of cytokines and
inflammatory mediators. Those systemic inflammatory events
cause activation of the endothelium, increase its permeability and
induce vascular dysfunction with secondary tissue edema and/or
tissue hypoperfusion, which sets the stage for multiple organ
dysfunction [1]. Although several anti-inflammatory pharmaco-
logical agents, including corticosteroids, aprotinin, antioxidants,
complement inhibitors and phosphodiesterase inhibitors, have
been proposed to inhibit the CPB-related inflammatory processes
and vascular dysfunction, none of them substantially improves the
clinical outcome of extracorporeal circulation [2].
Vascular reactivity after CPB has been investigated previously
in various vascular beds [3–7] although follow-up has been limited
to only a few hours after CPB. In rat mesenteric artery, 90 min of
CPB with 1 and 2.5 h recovery increased the contractile response
to phenylephrine and evoked endothelial dysfunction [3,8]. CPB
has been shown to decrease the myogenic reactivity of human
skeletal muscles arterioles [7], diminish the contractile response to
phenylephrine in human coronary and skeletal arteries [5,7] and
inhibit vasodilatation to acetylcholine in rat cerebral arteries [6].
Abnormality of vascular reactivity in the postoperative period is
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thought to substantially contribute to the development of organ
dysfunction after cardiopulmonary bypass.
FTY-720 (Fingolimod) is a non-selective sphingosine 1-phos-
phate (S1P) receptor modulator and immunosuppressive agent.
Thus far, the therapeutic potential of FTY-720 has been studied in
the setting of autoimmune disorders (multiple sclerosis, autoim-
mune neuritis, autoimmune glomerulonephritis) [9–12] and
transplantation medicine [12]. Probably, the inhibitory effect of
FTY-720 on the migration of lymphocytes, plays an important role
in its effect in autoimmune disorders and transplantation medicine
[9–14]. In addition, FTY-720 exerts diverse pharmacological
effects, including vascular effects and modulation of the inflam-
matory response, via activation of different S1P receptors on
endothelial cells, vascular smooth muscle cells, and leukocytes
[13].
The vascular effects of FTY-720 are dependent upon the type of
vascular bed and the prevalence of the S1P receptor subtypes. It is
thought that endothelium expresses S1P1 and S1P3 receptors,
which cause NO-mediated vasodilatation. However, S1P2 and
S1P3 receptors in vascular smooth muscle mediate a contractile
response via the Rho pathway. The systemic hypertensive
response evoked by S1P receptors agonists in rodents is thought
to be mediated via S1P3 receptors [15]. These, and possibly yet
undisclosed effects, result in FTY-720 decreasing ischemia-
reperfusion injury [16–21], enhancing endothelial barrier func-
tion, decreasing vascular permeability [22–27] and modulating
vascular function various rodent models and endothelial cells [26–
28]. Therefore, we hypothesize that administration of the S1P
receptor agonist FTY-720 will limit vascular dysfunction caused by
CPB. Hence, we investigated the effect of FTY-720 on inflam-
mation and vascular dysfunction in a rat model of experimental
CPB. First, we characterized the systemic inflammatory response
and vascular changes in small mesenteric and coronary arteries
induced by CPB during a 5 day follow-up period. Next, we
assessed whether FTY-720 and the S1P1R selective agonist, SEW-




Ethics statement. The protocols for animal care and use
were in accordance with the NIH Guide for the Care and Use of
Laboratory Animals and approved by the Animal Ethics
Committee of the University of Groningen (permit number
DEC4714). This study was performed in adult male Wistar rats
(body mass 478652g; Harlan, Zeist, The Netherlands). Animals
were housed under standard conditions (i.e. 12:12 h light:dark
cycle and ambient temperature 20–22uC) with free access to food
(standard rat chow; Hope Farms, Woerden, The Netherlands) and
drinking water throughout the study.
Experimental groups
Vascular effects of CPB. Animals (n = 78) were randomly
allocated to either CPB or Sham with a recovery period of either
one hour, one day, two or five days. Three animals (4%) were
euthanized after uncontrollable bleeding following attempted
cannulation. To reveal vascular effects induced by anesthesia
and surgery itself, which is expected to occur in both Sham and
CPB treated animals, we included naı¨ve untreated rats as
additional controls (n = 6). Control animals were sacrificed under
isoflurane anesthesia (2.5%). The final number of animals included
in the analysis were: CPB 1 hour (n = 13), Sham 1 hour (n = 7),
CPB 1 day (n = 11), Sham 1 day (n = 9), CPB 2 days (n = 8), Sham
2 days (n = 8), CPB 5 days (n = 6), Sham 5 days (n = 7) and Control
(n = 6).
Effect of S1P receptor agonists. Animals (n = 49) were
randomly allocated to one of the experimental groups, being either
CPB or Sham and to different treatments, being either vehicle,
0.5 mg/kg FTY720 or 0.5 mg/kg SEW2871 injected three hours
before the induction of anesthesia. After 1 day of recovery from
the procedure animals were euthanized. Thirty seven animals
survived and completed the study protocol: CPB FTY720 (n = 6),
Sham FTY720 (n = 7), CPB SEW2871 (n = 5), Sham SEW2871
(n = 6), Sham Vehicle (n = 6), CPB Vehicle (n = 7). The remaining
12 animals that did not survive the experimental procedure were
equally distributed amongst groups (data not shown). Deaths were
mainly due to technical problems (uncontrolled bleeding and
cannulation problems).
Experimental protocol
The experimental protocol consisted of the following parts:
anesthesia, preparation, extracorporeal circulation, a weaning and
a recovery period that was previously described [29,30]. Animals
that underwent the Sham procedure were subjected to the same
procedure as the animals in the CPB group, except for the
extracorporeal circulation; these animals maintained mechanically
ventilated throughout the procedure.
Anesthesia was induced with 2–3% isoflurane in O2/air (1:1 v/
v) before intubation and mechanical ventilation (Amsterdam
Infant Ventilator; HoekLoos, Amsterdam, The Netherlands).
Tidal volume was set to normocapnia (verified by arterial blood
gas analysis), with O2/air (1:2) at a ventilation rate of 50 min
21
(0.5 s inspiration time). Rectal temperature was kept at 37.5 6
0.5 uC, using an electrical heating pad. The left femoral artery was
cannulated (26-gauge catheter) for blood pressure monitoring. The
mean arterial pressure was kept between 70 and 100 mmHg by
adjusting the isoflurane concentration as necessary (typically
between 2.0–2.5%). Immediately before insertion of the arterial
line, 250 IU kg21 heparin was administered. The left carotid
artery was cannulated for arterial inflow using a 22-gauge catheter.
A multi-orifice 4.5 French cannula (adapted from a Desilets-
Hoffmann catheter, Cook Son, The Netherlands) was advanced
into the right heart using the right common jugular vein for access.
The tail vein was cannulated for the administration of intravenous
anesthetics, heparin, and protamine sulfate.
Extracorporeal circulation
Subsequently, extracorporeal circulation (ECC) was initiated in
the CPB group for 60 minutes. The set-up consisted of a
transparent polyvinylchloride venous reservoir, a peristaltic pump
(Pericor SF70, Germany), and a neonatal membrane oxygenator
(0140GM, Polystan, Vaerlose, Denmark). The oxygenator carried
a sterile, disposable three-layer artificial diffusion membrane,
made from hollow polypropylene fibers (Jostra AG, Hirrlingen,
Germany). All components were connected with polyethylene
tubing (1.6 mm inner diameter). The venous reservoir and heat
exchanger were sterilized prior to use. The circuit was primed with
15 ml of hydroxyethyl starch 60 mg ml21 solution (Voluven,
Fresenius Kabi, Bad Homburg, Germany). Animals were addi-
tionally heparinized (250 IU kg21) after the start of ECC. During
EEC, rats were anesthetized with intravenous fentanyl (125 mg
kg21), atracurium (0.5 mg kg21), and midazolam (2 mg kg21).
During CBP, blood oxygen saturation was monitored continuously
by a pulse oximeter. Targeted CBP flow was 100–110 mL kg21
min21, corresponding to 60–70% of normal cardiac output.
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Weaning and recovery
During the weaning period, ECC was terminated and
mechanical ventilation was initiated. Protamine (150 IU kg21
i.v.) was administered in order to neutralize heparin after which
cannulae were removed and the wounds sutured. Following
extubation, animals were kept under isoflurane anesthesia (0.8–
1.0%) for the first hour of recovery in order to stabilize. Animals
were euthanized at the end of the recovery period under isoflurane
anesthesia (2.5–3%).
Blood analysis
Blood gas analysis was performed in both studies and samples
(0.1ml) were drawn from the femoral artery at four time-points: at
the end of the preparation period (15 min before start of ECC),
twice during the ECC period (15 min after the start of ECC and
15 min before its end), and at 15 min after the end of ECC.
In addition, in the second part of the study, blood was taken for
full blood counts at the following times and sites: at the time of
injection of the compound (FTY-720, SEW-2871, vehicle groups,
from the tail vein), at the end of preparation period (15 min before
start of ECC, from the tail vein), at 45 min after the end of ECC
(from the femoral artery) and at euthanasia (24 hours after ECC,
from the aorta).
Blood gas analysis and cell count were performed at the central
laboratory of the University Medical Centre Groningen. Mean
arterial pressure (MAP) was monitored continuously during the
entire protocol via a catheter in a branch of the femoral artery
connected to a pressure transducer and a recorder.
Analysis of plasma IL-6
Plasma interleukin 6 (IL-6), as a marker of the inflammatory
response, was determined by Elisa according to the manufacturer’s
instructions (Rat IL-6 DuoSet, R&D system, Minneapolis, MN,
USA). Because of a limitation in the number of samples available
and the limited amount of samples that could be handled in one
run, a subset of samples was randomly chosen from the following
groups: Control (n = 7), Sham-Vehicle 1 hour (n = 6), CPB-
Vehicle 1 hour (n = 4), Sham-Vehicle 1 day (n = 5), CPB-Vehicle
1 day (n = 5), Sham 1 hour FTY-720 (n = 4), CPB 1 hour FTY-
720 (n = 4); Sham 1 day FTY-720 (n = 2), CPB 1 day FTY-720
(n = 4).
Vascular reactivity studies
At euthanization, all mesenteric loops and the heart were
removed and placed into a cold physiological saline solution.
Several segments of the third branch of the mesenteric superior
artery and the interseptal coronary artery were dissected, prepared
as ring vessel preparations (1.8–2.0 mm in length) and mounted on
two 40 mm stainless wires connected to force transducers in
individual organ bath chambers for isometric tension recordings in
a wire-myograph (Danish Myo Technology A/S, Aarhus, Den-
mark). The baths contained 6 ml of Krebs solution (pH = 7.4)
warmed to 37uC and perfused continuously with a gas consisting
of 95% O2 and 5% CO2. The vessels were subjected to the
standard normalization procedure [31] and left to equilibrate for
40 minutes until they reached a steady baseline. Briefly, arterial
segments were subjected to stretching stepwise by increasing the
distance between two wires in steps of 10 mm. The target
calculated transmural pressure was 100 mmHg for both mesen-
teric and coronary segments. The values of internal circumference
(micrometer reading, mm) and wall tension (force reading, mN/
mm) were registered. Then, the normalized internal circumference
(set to 0.8 of IC100, an internal circumference to a transmural
pressure of 100 mm Hg) was calculated for each vascular segment
[31]. Thereupon, vessels segments were equilibrated for 40
minutes to reach a steady baseline, followed by two consecutive
stimulations with potassium chloride (KCl, 60 mM). Only vessels
that demonstrated a reproducible contractile responses to KCl and
reproducible contractile responses to the agent employed (phen-
ylephrine or serotonin) throughout the experiment were used for
the evaluation of the relaxation to acetylcholine.
From each artery, four segments were used. The contraction to
phenylephrine (PE; 10 nM to 100 mM; mesenteric arteries) or
serotonin (SE; 10 nM to 100 mM; coronary arteries) was obtained.
Subsequently, these segments were precontracted with PE or SE
(both 10 mM) to a level of about 70% of Emax [31,32] and
endothelium-dependent relaxation to acetylcholine (ACh; 10 nM
to 300 mM) was assessed. Precontraction levels were found stable
throughout the protocol (data not shown). The maximal endothe-
lium-independent relaxation was assessed by addition of sodium
nitroprusside (SNP; 0.1 mM).
Drugs
Phenylephrine, serotonin, acetylcholine and sodium nitroprus-
side were purchased from Sigma (Sigma Aldrich, The Nether-
lands) and were dissolved in deionized water. Dimethyl sulfoxide
(DMSO) was purchased also from Sigma (Sigma Aldrich, The
Netherlands). FTY720 and SEW2871 were purchased from Tocris
Bioscience (United Kingdom) and were dissolved in 125 ml
DMSO and diluted with 375 ml saline (0.9% NaCl).
Statistical analysis
Data are expressed as mean 6 SEM. Contractile responses are
presented in mN and relaxations to ACh and SNP were calculated
as a percentage of preconstriction. Concentration-response curves
were plotted with SigmaPlot for Windows version 10.0 (Systat
Software, Chicago, Illinois, U.S.A.). Concentration-response
curves to PE, SE and ACh were characterized by area under
the curve (AUC) in arbitrary units (au). AUC values were
calculated by SigmaPlot. All statistical analyses were done with
SPSS 16.0.2 for Windows (SPSS Inc. Headquarters, Chicago,
Illinois, U.S.A.). Levene’s test was used to confirm the homoge-
neity of variance. If data were normally distributed, differences
were evaluated using Student’s t-test (independent sample t-test) or
One-Way ANOVA with posthoc Bonferroni test, where applica-
ble. Differences between concentration-response curves were
evaluated by Repeated-Measures ANOVA followed by Bonferroni
test. If normality test failed, results were analyzed using Mann-
Whitney Rank Sum test. Differences were considered significant at
P,0.05.
Results
Blood gas analysis and hemodynamics
The data on blood gas analysis are given in Table 1. In Sham
and CPB groups at baseline all parameters were in the normal
range. During ECC in CPB, the pH, bicarbonate (HCO23) level,
and base excess (BE) was decreased, while pCO2 was increased.
These findings may represent a moderate respiratory acidosis
(Table 1). The hematocrit was reduced in CPB, likely due to
hemodilution with the priming solution. After ECC, all param-
eters, except hematocrit, restored to baseline values and were not
different between Sham and CPB (Table 1). The parameters of
blood gas analysis in the groups pre-treated with FTY720 and
SEW2871 were similar to the corresponding Sham and CPB
groups (Table 1).
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At baseline, the MAP was not different between Sham and
CPB. During ECC in CPB animals, the MAP dropped and
remained significantly decreased until re-institution of normal
circulation (P,0.05, Figure 1). In Sham animals, both FTY720
and SEW2871 caused a pronounced and significant decrease of
MAP as compared with vehicle-treated Sham and untreated Sham
(P,0.05, Figure 1). However, while CPB substantially lowered
MAP, this was not further lowered by FTY720 and SEW2871.
Moreover, after weaning from CPB MAP recovered in Sham
CPB, but remained substantially decreased in Sham and CPB
animals treated with FTY720 and SEW2871 (Figure 1).
Blood cell counts
Table 2 shows the blood cell counts before, during and after the
experimental procedure. All values are corrected for the hemat-
ocrit in order to discard the effects of hemodilution. Both Sham
and CPB procedures evoked a substantial neutrophilia at the end
of extracorporeal circulation period, which returned towards
baseline levels after 24 hours of recovery (Table 2). Moreover, the
increase in Sham was significantly lower compared with CPB (P,
0.05, Sham-Vehicle vs CPB-Vehicle, Repeated measurements
ANOVA followed by LSD test). A similar pattern of post-
procedure neutrophilia was observed in Sham and CPB animals
treated with FTY720 or SEW2817 (Table 2).
In Sham animals, lymphocyte count seemed to decrease
gradually during the procedure and 24 h recovery. In CPB,
lymphocyte count increased during the procedure, which was
followed by a decrease of more than 50% after 24 h of the
recovery (P,0.05, One Way ANOVA followed by Bonferroni
test). As expected, treatment with FTY720 induced a pronounced
lymphopenia both in Sham and CPB (P,0.05, Table 2). This
effect was present already at the start of the extracorporeal
circulation and maintained throughout the 24 hour recovery
period, at which point the number of circulating lymphocytes was
decreased to 5–10% of the preoperative value (Table 2).
Treatment with SEW2871 induced similar dynamics in circulating
lymphocytes as observed in untreated CPB and SHAM animals
(P.0.05, Table 2). Finally, monocyte count did not differ
significantly between groups and was unaffected by CPB.
Thus, both Sham and CPB increased the number of circulating
neutrophils. CPB increases circulating lymphocyte number during
the procedure, which was followed by a substantial decrease at
24 hour of recovery. At 24 h recovery, FTY720 further decreased
the number lymphocytes by 90–95% as compared with the
preoperative value. In contrast, SEW-2871 did not further
decrease the circulating lymphocyte (additional to lymphopenia
registered in untreated CPB group).
IL-6 plasma concentration
The plasma IL-6 concentration in the untreated and FTY720-
treated groups are summarized in Table 3. In the Control group
the plasma level of IL-6 was not detected. IL-6 concentration was
slightly increased in Sham from 1 h up to 1 day of the recovery,
whereas CPB caused a significantly increase in IL-6 plasma
concentration at 1 h of recovery compared with Sham (P,0.05, t-
test), which returned to Sham level at 1 day of recovery. Notably,
the pre-operative treatment with a single application of the FTY-
720 did not affect the plasma concentration profile of IL-6 in both
Sham and CPB animals.
Effects of CPB and treatment with FTY720 and SEW2871
on contractile vascular reactivity
Mesenteric artery. Full concentration-response curves to
phenylephrine (PE) were constructed in mesenteric artery
(Figure 2, left panels) and data on maximal responses (Emax) are
specified in Table 4. Both Sham and CPB procedures reduced the
Figure 1. Data on mean arterial pressure in Sham and CPB groups during the experimental protocol. Abbreviations: MAP, mean arterial
pressure; CPB, cardiopulmonary bypass. Data are mean6SEM. a- indicates P,0.05, t-test; b- indicates P,0.05, Repeated Measurements Anova,
Bonferroni test.
doi:10.1371/journal.pone.0097196.g001
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contractility of mesenteric artery most prominently at 1 day of
recovery, whereas it returned to the baseline level at the 5th post-
procedure day (Figure 2A,2B; P,0.05 vs Control, Repeated
Measurements Anova, Bonferroni test). The decrease in contrac-
tility at 1 day recovery is also reflected by a decrease in the area
under the curve (Figure 2C; P,0.05 vs Control, One-Way Anova,
Bonferroni test) and Emax (Table 4; P,0.05, One-Way Anova,
Bonferroni test).
The effect of treatment with FTY720 and SEW2871 on
mesenteric contraction is presented in Figure 3 (left panels).
Treatment with FTY720 and SEW2871 increased the contractile
response to PE to a similar extent in Sham animals (FTY720:
P= 0.018 vs Vehicle group; SEW2871: P= 0.06 vs Vehicle group,
Repeated Measurements ANOVA, Bonferroni test). Moreover,
both treatments also increased PE-induced contraction in CPB,
although the effect of SEW2871 (P= 0.037 vs Vehicle group,
Repeated Measurements ANOVA, Bonferroni test) seemed more
prominent than that of FTY720 (P= 0.7 vs Vehicle group,
Repeated Measurements ANOVA, Bonferroni test).
Thus, both CPB and Sham procedures inhibit vascular
contractile responsiveness most prominently at 1 day of recovery,
suggesting that this is due to anesthesia/cannulation rather than
extracorporeal circulation. Both FTY720 and SEW2871 seem
effective in improving the contractile vascular function at 1 day of
recovery.
Coronary artery. Full concentration-response curves to
serotonin (SE) were constructed in coronary artery (Figure 2,
right panels) and data on maximal responses (Emax) to SE are
given in Table 3. Both Sham and CPB caused a right-shift in SE
concentration–response curves of coronary artery after short-term
recovery (i.e. at 1 h and 1 day recovery). The effect of treatment
with FTY720 and SEW2871 is presented in Figure 3 (right panels).
SEW2871 significantly increased the contractile response to SE in
both Sham and CPB as compared with corresponding Vehicle-
treated group (Sham: P,0.05, Repeated Measurements ANOVA,
Bonferroni test; CPB: P,0.05, t-test). FTY720 showed a tendency
to normalize contractile responsiveness in Sham (P,0.05, t-test),
but was without effect in CPB.
Thus, Sham and CPB inhibit contractile vascular reactivity of
coronary artery to SE at 1 day of recovery. Treatment with
SEW2871 normalized this loss of contractility, whereas FTY720
shows only moderate effectiveness.
Effects of CPB and treatment with FTY720 and SEW2871
on vascular relaxation
Mesenteric artery. Full concentration-response curves to
acetylcholine (ACh) were constructed in mesenteric artery
(Figure 4, left panels) and data on maximal response (Emax) to
acetylcholine and sodium nitroprusside are given in Table 4. The
Sham procedure did not affect the vascular relaxation to ACh
(Figure 4A, Table 4). In CPB, maximal ACh-mediated relaxation
was enhanced at 1 h of recovery, however with a later reduction at
2 days (Figure 4B,C). Generally, it was found that in mesenteric
artery relaxant reactivity to ACh was similar in Control and
Sham/CPB rats, suggesting that its endothelial function at 1 day of
recovery was intact (Figure 4). Endothelium-independent relaxa-
tion was unaffected in both Sham and CPB since the relaxation to
sodium nitroprusside was similar in all groups (Table 4).
Effects of the treatment with FTY720 and SEW2871 on
vascular relaxant reactivity are given in Figure 5. Interestingly,
both treatments seem to enhance total relaxation to ACh by about
25%, both in Sham and CPB. However, only in in CPB rats
treated with SEW2871 this effect reached statistical significance
(Figure 5; P= 0.026; CPB-SEW2871 vs CPB-Vehicle, Repeated
Measurements ANOVA, Bonferroni test).
Coronary artery. Full concentration-response curves to
acetylcholine (ACh) were constructed in coronary artery
(Figure 4, right panels) and data on maximal response (Emax) to
acetylcholine and sodium nitroprusside are given in Table 4.
During the 5 days recovery period, the total ACh mediated
dilatation was mainly unaltered in both Sham and CPB compared
to control rats (Figure 4D–F), while in CPB the maximal response
to ACh was significantly increased after 1 h of recovery (Table 4).
Endothelium-independent relaxation was unaffected since the
relaxant responses to sodium nitroprusside were similar in all
groups (Table 4).
Effects of the treatment with FTY720 and SEW2871 on
vascular relaxant reactivity are given in Figure 5 (right panels).
Both treatments displayed a tendency to enhance the total
relaxation to Ach by about 20%, while their efficacy was different
in Sham and CPB. SEW2871 was more effective in Sham (P,
0.05, vs Sham-Vehicle, t-test; Emax in Sham SEW2871:
72.464.2%; Emax in Sham Vehicle: 51.567.0%) and FTY720
was significantly more effective in CPB (P, 0.05, vs CPB-Vehicle,
Repeated Measurements ANOVA, Bonferroni test).
Thus, in both mesenteric and coronary artery during 5 days of
recovery, the relaxant reactivity was similar in Control and Sham/
CPB rats. Nevertheless, both FTY720 and SEW2871 seemed to
improve the vascular relaxant response to ACh both in Sham and
CPB.
Discussion
The present work studied the effects of treatment with FTY720
and SEW2871, two different S1P receptor agonists, on vascular
reactivity in an experimental rat model of cardiopulmonary
Table 3. The IL-6 plasma concentration (mmol/L) in untreated controls, Sham and CPB groups Vehicle and treated with FTY-720
after 1 hour and 24 hours recovery period.
Group 1 hour recovery 24 h recovery
Healthy controls Not detected –
Sham-Vehicle 2.8 6 2.2 5.7 6 3.3
CPB-Vehicle 4449 6 589 2.7 6 1.8
Sham FTY-720 4.6 6 2.2 5.6 6 5.6
CPB FTY-720 3793 6 593a 9.1 6 5.2
Abbreviations: CPB, cardiopulmonary bypass; 24 h, scarification at 24 h later the end of the extracorporeal circulation.
a- p,0.05 vs CPB, t-test.
doi:10.1371/journal.pone.0097196.t003
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Figure 2. Contractile reactivity after short and long-term recovery following Sham or CPB. Left panels: contractile reactivity of mesenteric
arteries to PE. A: concentration-response curves for Sham groups, mN; B: concentration-response curves for CPB groups, mN; C: AUC values of the
contractile responses to PE, au. Right panels: contractile reactivity of coronary arteries to SE. D: concentration-response curves for Sham groups, mN;
E: concentration-response curves for CPB groups, mN; F: AUC values of the contractile responses to SE, au. Abbreviations: CBP, cardiopulmonary
bypass; PE, phenylephrine; SE, serotonin. Data are mean6SEM. a- indicates P,0.05 vs Control-Vehicle, Repeated measurements ANOVA, Bonferroni
test; b- indicates P,0.05 vs CPB-Vehicle, One Way ANOVA, Bonferroni test.
doi:10.1371/journal.pone.0097196.g002
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bypass. In accordance with the proposed mechanisms of action,
we found FTY720, but not SEW2871, lowers circulating
lymphocyte count. Both FTY720 and SEW2871 were found to
cause a pronounced reduction in blood pressure during the
experimental protocol in both Sham and CPB. Further, we found
the CPB-related surgical procedures and/or extended anesthesia
to induce extensive and protracted changes in the contractility of
small vessels, as contractility of both mesenteric and coronary
artery was inhibited, which was most prominent at 1 day of
recovery. Preoperative administration of both FTY720 and
SEW2871 normalized the vascular reactivity by increasing the
vascular responsiveness to PE (mesenteric artery) and SE (coronary
artery). In contrast, the vascular relaxation to ACh was essentially
unchanged in Sham and CPB during 5 days of recovery. However,
both FTY720 and SEW2871 increased ACh induced vascular
relaxation in both vascular beds by about 20–25%. Thus, both
compounds evoked hypotension, improved vascular contractile
and relaxant responsiveness, yet differentially decreased the
amount of lymphocytes in the peripheral blood. These data
suggest that the observed systemic vascular treatment effects of
FTY720 and SEW2871 were independent from lymphopenia but
rather involved the modulation of vascular S1P1 receptors.
Vascular reactivity after CPB
Vascular dysfunction contributes to multiple organ dysfunction
syndrome after CPB and is therefore considered to be a relevant
target of therapy. We found that contractility of both mesenteric
and coronary arteries was impaired by both experimental
procedures (i.e. Sham and CPB), most prominently at one day
of recovery. The finding that both Sham and CPB negatively
affects the vascular contractile function, suggests that the minor
surgical procedures and/or extended anesthesia induce these
extensive and protracted changes in the contractility of small
vessels, rather than ECC. In addition, we found that the relaxant
vascular function was much less affected: only the relaxant
function of mesenteric arteries was briefly affected following CPB
and only minor effects of surgery (i.e. sham and CPB) were found
on the relaxant function of the coronary arteries. Collectively, our
data suggest that anesthesia and cannulation have a long-lasting
impact on the vasoresponsiveness of small arteries, which warrants
further investigation into its mechanism and the contribution of
different types of anesthetics.
Figure 3. Effect of S1P receptor agonist pretreatment with FTY720 and SEW2871 on contractile responses at 1 day following
recovery from Sham or CPB. Left Panels: responses to PE in mesenteric arteries. Right panels: responses to SE in coronary arteries. Abbreviations:
CPB, cardiopulmonary bypass; PE, phenylephrine; SE, serotonin. Data are mean6SEM. a- indicates P,0.05 SEW2871 vs Vehicle, Repeated
Measurements ANOVA, Bonferroni test (P = 0.007 for coronary artery and P= 0.037 for mesenteric artery); b- indicates P= 0.018 FTY720 vs Vehicle,
Repeated Measurements ANOVA, Bonferroni test; c- indicates P= 0.04, SEW2871 vs Vehicle, t-test; d- indicates P = 0.028 SEW2871 vs Vehicle, t-test; e-
indicates P = 0.01 FTY720 vs Vehicle, t-test.
doi:10.1371/journal.pone.0097196.g003
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Figure 4. Relaxant reactivity after short and long-term recovery following Sham or CPB. Left panels: relaxant reactivity of mesenteric
arteries to ACh. A: concentration-response curves for Sham groups, % of relaxation; B: concentration-response curves for CPB groups, % of relaxation;
C: AUC values of the relaxant responses to ACh, au. Right panels: relaxant reactivity of coronary arteries to ACh. D: concentration-response curves for
Sham groups, % of relaxation; E: concentration-response curves for CPB groups, % of relaxation; F: AUC values of the relaxant responses to ACh, au.
Abbreviations: CBP, cardiopulmonary bypass; PE, phenylephrine; SE, serotonin. Data are mean6SEM. a- indicates P,0.05 vs Control-Vehicle, t-test. b-
indicates P,0.05 vs Sham 2 days, t-test.
doi:10.1371/journal.pone.0097196.g004
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Influence of S1P-receptor agonists on the amount of
lymphocytes
Although S1P is of importance in the entire human body, it is a
major regulator of the vascular and immune system. In this
respect, the immunomodulatory effects of S1P agonists have been
associated with the inhibition after S1P receptor activation of the
egress of lymphocytes from secondary lymphoid organs to
peripheral blood [33]. FTY720 is considered a potent non-
selective S1P receptor agonist [9–12]. Upon binding to the S1P
receptor, FTY720 induces internalization of the receptors and
induces their degradation, leading to a downregulation in the
number of S1P receptors [34]. By reducing the number of
receptors, FTY720 can be considered as a functional antagonist.
SEW2871 is a highly selective S1P1 receptor agonist that in
contrast to FTY720 does not induce degradation of its receptor
after internalization and is thereby not able to downregulate S1P1
receptors [34–35]. We found that FTY720 induced a profound
decrease in the amount of circulating lymphocytes, but not in
neutrophils or monocytes. FTY720-induced lymphopenia was
present at the onset of extracorporeal circulation (approximately
4 hour after the injection) and lasted for (at least) 24 hours
thereafter. In contrast, the number of circulating lymphocytes was
not affected by SEW2871. Further, CPB induced a marked
systemic inflammatory response as evidenced with the increase in
plasma IL-6, which was unaffected by the pre-operative treatment
with the single dose of FTY-720. Collectively, the above data
strongly indicate that the reported vascular effects of FTY720 and
SEW2871 are independent of its effect on immune cells.
Effect on Mean Arterial Blood Pressure
Both FTY720 and SEW2871 decreased the MAP significantly
during the operative period, which most likely involves their action
on S1P1 receptors. Indeed, activation of S1P1 (and S1P3) receptors
on endothelium enhances the production of nitric oxide and has
vasodilatory effects [36]. Alternatively, the reduction in MAP by
FTY720 might involve signaling through S1P3 receptors, as
described previously [37] or it might be result from S1P3 receptors
induced bradycardia [38]. We did not record heart rate and
therefore we cannot report whether the pretreatment with the
experimental compound also caused bradycardia in our experi-
mental settings. Further, FTY720 may inhibit the secretion of
prostanoids, including contractile prostaglandins such as throm-
boxane A2, via a receptor-independent inhibition of phospolipase
A2, a key enzyme of arachidonic acid-derived eicosanoid
formation [39]. Taken together, both FTY720 and SEW2871
similarly decreased the blood pressure during surgery, which
suggests it is mediated mainly by S1P1 receptor mediated
signaling.
Figure 5. Effect of S1P receptor agonist pretreatment with FTY720 and SEW2871 on relaxant reactivity at 1 day following recovery
from Sham or CPB. ACh-induced relaxation was studied in mesenteric arteries (left panels A and B) and coronary arteries (right panels C and D).
Abbreviations: CPB, cardiopulmonary bypass, ACh, acetylcholine. Data are mean6SEM. a- indicates P = 0.026 SEW2871 vs Vehicle, Repeated
Measurements ANOVA, Bonferroni test; b- indicates P = 0.018 FTY720 vs Vehicle Repeated Measurements ANOVA, Bonferroni test; c- indicates P = 0.03
SEW2871 vs Vehicle, t-test; d- indicates P = 0.03 FTY720 vs Vehicle, t-test.
doi:10.1371/journal.pone.0097196.g005
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Effect of S1P receptor agonists on contractile vascular
reactivity
The depressed mesenteric contractility was used to evaluate the
potential of agonists of S1P receptors to modulate vascular
dysfunction in CPB. We show that injection of a S1P1 receptor
agonist improves the vascular contractile and relaxant function of
mesenteric and coronary arteries and thereby, at least in part,
preclude the negative effects of surgery and CPB on these vessels.
Despite the differential effects of FTY720 and SEW2871 on
circulating lymphocytes in the present study, both compounds
shared a similar effect on vascular reactivity and blood pressure,
which suggests that the effects on the vascular function occur
independently of immunological changes (i.e. lymphopenia), but
rather involve modulation of vascular S1P receptors.
The comparable effect of both FTY720 and SEW2871 on
vascular contractility suggests the involvement of S1P1 receptor-
dependent mechanism, whereas vascular smooth muscle were
reported to express mainly S1P2 and S1P3 receptors that mediate
vasoconstriction [40–43] through activation of the phospholipase
C, myosin light chain kinase and/or Rho-associated kinase-
dependent inhibition of myosin light chain phosphatase [44–47].
However, other studies found the involvement of S1P1 receptors
in the regulation of contractile reactivity [44–47] and S1P agonist
were found recently to evoke vasoconstriction of the afferent renal
arterioles via S1P1 and S1P2 receptors with involvement of the L-
type voltage-dependent calcium channels [48]. Further, S1P
induces COX-2 expression in vascular smooth muscle cells, which
seems partially mediated via S1P1 receptors [49]. Thus, S1P1
receptor may be more prominently involved in VSMC regulation
than reported so far. Alternatively, the similar effect of FTY720
and SEW2871 on VSM contractility may be dependent on S1P
receptors expressed on the endothelium. Indeed, FTY720 evokes
endothelium dependent VSMC contraction most likely via COX/
thromboxane A2 route and sphingosine kinase [50]. Indeed,
hyporeactivity of VSM to adrenomimetics may depend on
changes in the endothelium, as found in septic shock [51].
Possibly, S1P1 agonist thus improve postoperative vascular
contractile reactivity via modulation of this endothelium-depen-
dent mechanisms.
Effect of S1P receptor agonists on relaxant vascular
reactivity
CPB was priory reported to cause a pronounced vascular
dysfunction [52–54]. In several rat models, CPB induced
endothelial dysfunction, mainly after 60–90 min of recovery
[55,56]. However, in our study the endothelium-dependent
relaxation to ACh did not differ between Sham and CPB rats
and was comparable to that in untreated Controls, demonstrating
that endothelial function was intact at 1 day post-CPB. The lack of
the endothelial vascular dysfunction in our study may be explained
by differences between models and experimental protocols. The
model we employed is a modification of the previously widely
published model (Samarska et al. 2013, J Pharmacol Toxicol
Methods). Our model differs on three points: miniaturization of
the extracorporeal circuit to 15 ml avoids both blood transfusion
and excessive hemodilution. Moreover, our model employs
arterial inflow via the left common carotid artery to the aortic
arch instead of inflow via the tail artery. All these factors may
influence CPB-mediated endothelial dysfunction. In addition,
differences with previously employed models regarding duration of
the extracorporeal circulation and the postoperative recovery
period may influence vascular reactivity. However, similar to the
clinical setting, CPB, but not Sham, featured the activation of a
systemic inflammatory response, demonstrating the fitness of our
model to preclinically evaluate the potential of experimental
therapeutic interventions.
Despite the lack of the endothelial dysfunction, FTY720 and
SEW2871 both enhanced total relaxation to ACh in all groups,
although augmentation of the endothelium-dependent relaxation
was most pronounced in CPB. Most likely, in coronary artery, the
enhanced relaxation to FTY720 and SEW2871 is caused by
activation of S1P1 and/or S1P3 receptors on endothelial cells,
which evoke the release of NO through the activation of eNOS
[16–18]. On the other hand, relaxation of mesenteric arteries
depends on EDHF rather than NO, which is only a minor
mediator of its endothelium-dependent relaxation. Thus, in
addition to amplification of the NO production, FTY720 and
SEW2871 may have enhanced S1P1-receptor mediated increase in
EDHF production or its action. Indeed, S1P was shown to activate
large-conductance Ca(2+)-activated K(+) channel in a G-protein
independent manner [47], but its effects on EDHF production
needs further exploration. Nevertheless, because both experimen-
tal compounds exerted highly comparable effects, it seems
conceivable that vascular effects are mainly mediated through
S1P1 receptors.
In conclusion, we reveal that in the rat (1) CPB impairs vascular
contractility in small arteries, which is due to both the surgical and
anesthetic procedure and most prominent at one day following
surgery, (2) CPB has a limited effect on vascular relaxant function
and (3) vascular dysfunction following CPB is relieved by pre-
operative treatment with FTY720 and SEW2871.
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